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CORONAVIRUS
Rapid implementation of mobile technology for
real-time epidemiology of COVID-19
David A. Drew1*, Long H. Nguyen1*, Claire J. Steves2,3, Cristina Menni2, Maxim Freydin2,
Thomas Varsavsky4, Carole H. Sudre4, M. Jorge Cardoso4, Sebastien Ourselin4, Jonathan Wolf5,
Tim D. Spector2,5†, Andrew T. Chan1,6†‡, COPE Consortium§
The rapid pace of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) presents challenges to the robust collection of population-scale
data to address this global health crisis. We established the COronavirus Pandemic Epidemiology (COPE)
Consortium to unite scientists with expertise in big data research and epidemiology to develop the
COVID Symptom Study, previously known as the COVID Symptom Tracker, mobile application. This
application—which offers data on risk factors, predictive symptoms, clinical outcomes, and geographical
hotspots—was launched in the United Kingdom on 24March 2020 and the United States on 29March 2020
and has garnered more than 2.8 million users as of 2 May 2020. Our initiative offers a proof of concept
for the repurposing of existing approaches to enable rapidly scalable epidemiologic data collection
and analysis, which is critical for a data-driven response to this public health challenge.
T
he exponentially increasing number
of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infections
has led to “an urgent need to expand
public health activities in order to eluci-
date the epidemiology of the novel virus and
characterize its potential impact” (1). Under-
standing risk factors for infection and pre-
dictors of subsequent outcomes is crucial to
gain control of the coronavirus disease 2019
(COVID-19) pandemic (2). However, the speed
at which the pandemic is unfolding poses an
unprecedented challenge for the collection of
exposure data to characterize the full breadth
of disease severity, hampering efforts for time-
ly dissemination of accurate information to
affect public health planning and clinicalman-
agement. Thus, there is an urgent need for an
adaptable real-time data-capture platform to
rapidly and prospectively collect actionable
high-quality data that encompass the spectrum
of subclinical and acute presentations and
identify disparities in diagnosis, treatment,
and clinical outcomes. Addressing this priority
will allow for more accurate estimates of dis-
ease incidence, inform risk mitigation strat-
egies, facilitate allocation of scarce testing
resources, and encourage appropriate quar-
antine and treatment of those afflicted.
An evolving body of literature suggests that
COVID-19 incidence andoutcomes vary accord-
ing to age, sex, race, ethnicity, and underlying
health status, with inconsistent evidence sug-
gesting that commonly used medications—
such as angiotensin-converting enzyme inhib-
itors, thiazolidinediones, and ibuprofen—may
alter the natural disease course (3–9). Further,
symptoms of COVID-19 varywidely, with fever
and dry cough reportedly the most prevalent,
though numerous investigations have dem-
onstrated that asymptomatic carriage is a
significant determinant of community spread
(5–7, 10–13). In addition, the full spectrum of
clinical presentation, which is still being char-
acterized, may differ markedly across patient
subgroups.Recent advisories fromtheAmerican
Gastroenterological Association, the American
Academy of Otolaryngology–Head and Neck
Surgery, and the British Geriatrics Society
have emphasized the potential association
between COVID-19 infection and previously
underappreciated gastrointestinal symptoms
(e.g., nausea, anorexia, and diarrhea), loss
of taste and/or smell, and common geriatric
syndromes (e.g., falls and delirium). The pan-
demic has considerably outpaced our collec-
tive efforts to fully characterize who is most
at risk or may suffer the most serious sequelae
of infection.
Mobile phone applications and web-based
tools facilitate self-guided collection of population-
level data at scale (14), the results of which
can be rapidly redeployed to inform partic-
ipants of urgent health information (14, 15).
Both technologies are particularly advanta-
geous when many individuals are advised to
maintain physical distance from others (16).
Such digital tools have already been applied
inmore controlled research settings, and these
studies benefit from greater lead time for field
testing, question curation, and recruitment.
Although many digital collection tools for
COVID-19 are being developed and launched
in the Unites States and abroad (see http://
mhealth-hub.org/mhealth-solutions-against-
covid-19 for a continuously updated resource
list from the European Union and the World
Health Organization), including some in part-
nership with government health agencies
such as the Centers for Disease Control and
Prevention, most applications have largely
been configured to offer a single assessment
of symptoms to tailor semipersonalized rec-
ommendations for further evaluation. Infec-
tious disease surveillance web-based tools
(e.g., http://flunearyou.org) have been rap-
idly adapted for COVID-19–specific collection
(e.g., http://covidnearyou.org). Alternatively,
web portals have been developed for research-
ers to report patient-level information on
behalf of participants already enrolled in
clinical registries (e.g., ccc19.org). Integra-
tion with approaches that use remote data
capture (e.g., wearable technology or symptom
checkers such as real-time reporting ther-
mometers) is also being considered. Although
these approaches offer critical public health
insights, they are often not tailored for the
type of scalable longitudinal data capture that
epidemiologists need to perform comprehen-
sive, well-powered investigations.
To meet this challenge, we established a
multinational collaboration, the COronavirus
Pandemic Epidemiology (COPE) Consortium,
composed of leading investigators from sev-
eral large clinical and epidemiological cohort
studies. COPE brings together amultidiscipli-
nary team of scientists with expertise in big
data research and translational epidemiology
to investigate the COVID-19 pandemic in a
large and diverse patient population. Several
large cohorts have already agreed to join these
efforts, including the Nurses’ Health Study
series, the Growing Up Today Study (GUTS),
the Health Professionals Follow-Up Study
(HPFS), TwinsUK, American Cancer Society
Cancer Prevention Study 3 (CPS-3), theMulti-
ethnic Cohort Study, the California Teachers
Study (CTS), the BlackWomen’sHealth Study
(BWHS), the Sister Study, Aspirin in Reducing
Events in the Elderly (ASPREE), the Stanford
Nutrition Studies, the Gulf Long-term Follow-
up (GuLF) Study, the Agricultural Health
Study, the National Institute of Environmen-
tal Health Sciences Environmental Polymor-
phismsRegistry, the Predicting Progression of
DevelopingMyeloma in aHigh-Risk Screened
Population (PROMISE) study, and the Pre-
cursor Crowdsourcing (PCROWD) study. To
aid in our data harmonization efforts in the
United States, we developed the COVID Symp-
tom Study (previously known as the COVID
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Fig. 1. Schematic of the participant workflow. After downloading the COVID
Symptom Study app and providing consent, users are prompted to enter
baseline demographic and clinical information and are serially queried about
new or ongoing symptoms, testing results, and extent of isolation. Health care
workers offer additional information about the intensity of their patient
interactions, potential exposure to infected patients, and use of PPE.
With informed consent, users also participating in a variety of ongoing
cohorts or clinical trials (Nurses’ Health Study, TwinsUK, and others) have
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Fig. 2. COVID Symptom Study use, reported symptoms, and testing results
according to geographic location in the United Kingdom. Between 24 and
29 March 2020, more than 1.6 million unique individuals downloaded the application
and shared clinical and demographic information, as well as daily symptoms and
high-intensity occupational exposures (blue map). Population density of those
presenting with any symptoms (left purple map) varied according to region, with
widespread reports of fatigue, cough, and diarrhea, followed by anosmia and,
relatively infrequently, fever (inset). Examination of individuals who reported complex
symptoms (right purple map), defined as having cough or fever and at least
one other symptom (diarrhea, anosmia, or fever), reveals areas that potentially need
more testing. For the subset of the population that received a COVID-19 test
(black map), areas with larger proportions of positive tests (orange map) appear to
coincide with areas in which high proportions of the population reported complex
symptoms. By contrast, some areas with low prevalence of complex symptoms have
received higher rates of testing and, consequently, more negative tests (green map).
This example of real-time visualization of data captured by the COVID Symptom
Study may help public health and government officials reallocate resources,
identify areas with unmet testing needs, and detect emerging hotspots.
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Symptom Tracker) mobile app with in-kind
contributions from Zoe Global Ltd., a digital
health care company, and academic scientists
from Massachusetts General Hospital and
King’s College London. By leveraging the
established digital backbone of an applica-
tion used for personal nutrition studies, the
COVID Symptom Study app was launched
in the United Kingdom on 24 March 2020
and became available in the United States on
29March 2020 (https://covid.joinzoe.com/us).
The COPE Consortium is committed to the
shared international pursuit of combating
COVID-19 and has worked with scientific
collaborators and thought leaders in real-time
epidemiology to prioritize data harmonization
and sharing as part of the Coronavirus Census
Collective (17).
The COVID Symptom Study enables self-
reporting of data related to COVID-19 expo-
sure and infections (Fig. 1). On first use, the app
queries location, age, and core health risk fac-
tors.Daily prompts query for updates on interim
symptoms, health care visits, and COVID-19
testing results. For those self-quarantining or
seeking health care, the level of intervention
and related outcomes are collected. Individu-
als without obvious symptoms are also encour-
aged to use the app. Through pushed software
updates, we can add or modify questions in
real time to test emerging hypotheses about
COVID-19 symptoms and treatments. Notably,
participants enrolled in ongoing epidemio-
logic studies, clinical cohorts, or clinical trials
can provide informed consent to link survey
data collected through the app to their preexist-
ing study cohort data and any relevant bio-
specimens in aHealth Insurance Portability and
Accountability Act (HIPAA)–compliant and
General Data Protection Regulation (GDPR)–
compliant manner. A specific module is also
provided for health care workers to determine
the intensity and type of their direct patient
care experiences, the availability and use of
personal protective equipment (PPE), andwork-
related stress and anxiety.
Through rapid deployment of this tool, we
can gain key insights into population dynamics
of the disease (Fig. 2). By collecting participant-
reported geospatial data, highlighted as a crit-
ical need for pandemic epidemiologic research
(15), we can rapidly identify populations with
highly prevalent symptoms in regions that
may emerge as outbreak hotspots. An early
snapshot of the first 1.6 million users in the
United Kingdom over the first 5 days of use
confirms the variability in symptoms reported
across suspected COVID-19 cases and is useful
for generating and testing broader hypothe-
ses. At the time, users had a mean age of 41,
ranged from 18 to 90 years old, and were 75%
female. Graphic visualization of our initial
results (Fig. 3) demonstrates that among those
reporting symptoms by 27 March 2020 (n =
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Fig. 3. Symptoms reported through the COVID Symptom Study app. By 27 March 2020, 265,851 individuals
in the United Kingdom reported any symptom potentially associated with COVID-19 (top). Participants
provided data on whether they were tested for COVID-19, as well as the test result. 1176 individuals reported
having received a COVID-19 test (0.4% of those with symptoms). Symptom frequencies among those
who tested positive (middle; n = 340) versus negative (bottom; n = 836) are shown.
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265,851 individuals), the most common symp-
toms were fatigue and cough, followed by
diarrhea, fever, and anosmia. Shortness of
breath was reported relatively rarely. Only
0.4% (n = 1176) of individuals reporting pos-
sible COVID-19 symptoms reported receiv-
ing a quantitative polymerase chain reaction
test for COVID-19.
A comparison of symptomatic users who
reported receiving a test within the initial
launch period generated several hypotheses
for future study with the growing dataset. The
frequency of cough or fatigue alone or in com-
bination commonly led to testing but was not
a particularly accurate predictor of a positive
test. Similarly, no individuals who reported
diarrhea in the absence of other symptoms
tested positive. Notably, more complex pre-
sentations with cough and/or fatigue and at
least one additional symptom, including less
commonly appreciated complaints such as
diarrhea and anosmia, appeared to be enriched
among those with positive test results relative
to those with negative results. In particular,
anosmia may be a more predictive symptom,
as it was more common than fever in indi-
viduals who tested positive. Indeed, in subse-
quent analyses with a larger sample set, we
have shown that anosmia appears to be a
strong predictor for COVID-19 (18). By con-
trast, fever alone was not particularly dis-
criminatory. However, when fever was present
in combination with less appreciated symp-
toms, a greater frequency of positive tests
was observed. These findings suggest that
perhaps individuals with complex or multiple-
symptom (three or more) presentations should
be prioritized for testing. Concerningly, 20%
of individuals reported complex symptoms
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Fig. 4. Predicting COVID-19 cases on the basis of real-time symptom reporting
in Wales, United Kingdom. This time series (bar graph) displays the number
of new confirmed cases (gray bars) reported by the Public Health Wales
NHS Trust between 31 March 2020 and 20 April 2020. After 2 April, case
numbers appear to have declined through 5 April. However, our symptom-based
prediction model (18), developed from symptom reports from untested users
of the COVID Symptom Study app, showed a high proportion of predicted
COVID-19 cases in southern Wales on 1 April [dark red areas in (A)]. Six days
later, Welsh health authorities reported a subsequent peak in cases over a
4-day period (6 to 9 April), driven primarily by these southern regions
(colored bars). By 10 April, new confirmed cases across Wales declined.
However, on the basis of reported symptoms (B), regions in South Wales
still had high predicted levels of COVID-19, which became apparent as a
second spike in confirmed cases between 15 and 16 April. As of 20 April (C),
predicted COVID-19 prevalence across Wales according to symptom reporting
appears to be low, which corresponds to a flattening of the cumulative
incidence curve. However, several regions in southern Wales still have relatively
high reports of symptoms and appear at risk for subsequent cases of COVID-19.
Black dots on the maps represent the relative proportion of positive tests
reported by health authorities across Wales that day by region. The prediction
mapping included data from 1,339,670 users of the COVID Symptom Study on
1 April; 998,244 users on 10 April; and 1,234,918 users on 20 April. Public
Health Wales NHS Trust data were current as of 21 April 2020 at 13:00 local
time, taken from the “Rapid COVID-19 Virology - Public” dashboard (accessed
via https://phw.nhs.wales/), and downloaded on 22 April 2020 at 12:30 p.m.
Eastern Standard Time.
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(cough and/or fatigue plus at least one of
anosmia, diarrhea, or fever) but had not yet
been tested, representing a substantial pop-
ulation that appears to be at elevated risk
for the disease. Additional work is warranted
to confirm whether complex or multiple-
symptom cases can accurately predict COVID-19
incidence.
Building on these initial findings, our team
subsequently developed a weighted prediction
model based on the symptoms of more than
2 million individual app users (18). By using
this predictionmodel, we demonstrate the po-
tential utility of the COVID Symptom Study
app to collect data for long-term studies as well
as for immediate public health planning. In
southernWales in the United Kingdom, users
reported symptoms that predicted, 5 to 7 days
in advance, two spikes in the number of con-
firmed positive COVID-19 cases reported by
public health authorities (Fig. 4). Conversely,
a decline in reports of symptoms preceded
a drop in confirmed cases by several days.
These results demonstrate that this app pro-
spectively captures the dynamics of COVID-19
incidence days in advance of traditional mea-
sures, such as positive tests, hospitalizations,
or mortality. We are currently planning ad-
ditional studies using a broadly representa-
tive sample of individuals who will undergo
uniform COVID-19 testing to further vali-
date our approach to symptom-based mod-
eling of incidence. These data demonstrate
compelling evidence for the potential pre-
dictive power of our approach, which will
improve asmore data are collected to inform
the model. Further, our data highlight the
potential utility of real-time symptom track-
ing to help guide allocation of resources for
testing and treatment as well as recommen-
dations for lockdown or easement in spe-
cific areas.
With additional data collection, we will also
apply big data approaches (e.g.,machine learn-
ing) to identify emerging patterns in dynam-
ic settings of exposure, onset of symptoms,
disease trajectory, and clinical outcomes.
Our launch of the app within several large
epidemiology cohorts that have previously
gathered longitudinal data on lifestyle, diet
and health factors, and genetic information
will allow investigation of a much broader
range of putative risk factors for COVID-19
outcomes. With additional follow-up, we will
also be positioned to investigate long-term
effects of COVID-19, including mental health,
disability, mortality, and financial outcomes.
Mobile technology can also supplement re-
cently launched clinical trials or biobanking
protocols already embedded within clinical
settings. In collaboration with the Stand Up
to Cancer foundation, we have also devel-
oped a strategy to track information among
individuals living with cancer, including those
enrolled in clinical trials. At theMassachusetts
General Hospital and Brigham and Women’s
Hospital, we are deploying the tool within
several clinical studies, centralized biobank-
ing efforts, and health care worker surveil-
lance programs. Health care workers are
particularly vulnerable to COVID-19’s effects
beyond infection, including work hazards
from PPE shortages, emotional stress, and
absenteeism. Real-time data generation fo-
cused within these populations will be criti-
cal to optimally allocate resources to protect
our health care workforce and assess its
efficacy.
Even so, our approach has limitations. We
recognize that a smartphone application does
not represent a random sampling of the pop-
ulation. However, this is an inherent limita-
tion of any epidemiologic study that relies on
voluntary participation. Our approach has the
benefit of allowing rapid deployment across
a large cross section of the population during
a major public health crisis. With time and
continued use, the large number of participants
will include a sufficient quantity of userswithin
key subgroups such that we can adjust our
methodology for potential sources of confound-
ing. By engaging cohorts with underrepre-
sented populations, such as the BWHS in the
United States, we also hope to leverage exist-
ing investigator-participant relationships to
encourage enrollment of individuals from
populations that have traditionally been chal-
lenging to recruit. Moreover, by encouraging
longitudinal, prospective data collection, we
can capture associations based on within-
person variation over time, a notable advan-
tage over repeated cross-sectional surveys that
introduce considerable between-person varia-
tion. In the near future, we hope to release our
app as fair-use open source software to facili-
tate translation and development in other re-
gions.We have begunworkingwith colleagues
inCanada, Australia, and Sweden to implement
this tool within their countries. We have also
developed a practical toolkit to assist clinical
researchers with local institutional review
board and regulatory approval to facilitate
deployment within research studies (www.
monganinstitute.org/cope-consortium). This
toolkit includes full details of the mobile app’s
questions, consent documents, privacy policies,
and terms of use. With broader implementa-
tion, data generated from the COVID Symptom
Study app are increasingly being linked to
the public health responsewithin the National
Health Service (NHS) in the United Kingdom.
The app is endorsed by theWelsh government,
NHSWales, the Scottish government, andNHS
Scotland, and our scientific team updates the
U.K. chief scientific officer daily. We are work-
ing to develop a similar approach in the United
States. However, the lack of a national health
care system has required a strategy focused
on engaging local public health leaders. For
example, we have partnered with the Uni-
versity of Texas School of Public Health to
conduct statewide surveillance to support pub-
lic health decision-making, especially as the
Texas state government begins softening miti-
gation strategies.
Our approach demonstrates a proof of con-
cept for rapid repurposing of existing data
collection methods to implement scalable
real-time collection of population-level data
during a fast-moving global health crisis. We
call on our colleagues to work with us so that
we may deploy all of the tools at our disposal
to address this unprecedented public health
challenge.
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